KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Non-Current Deferred Tax Liability (2017 - 2025)

Novartis Ag's Non-Current Deferred Tax Liability history spans 4 years, with the latest figure at $2.4 billion for Q4 2024.

  • For Q4 2024, Non-Current Deferred Tax Liability rose 7.61% year-over-year to $2.4 billion; the TTM value through Dec 2024 reached $2.4 billion, up 7.61%, while the annual FY2024 figure was $2.4 billion, 7.61% up from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2024 was $2.4 billion at Novartis Ag, up from $2.2 billion in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $2.7 billion in Q4 2022 and bottomed at $2.2 billion in Q4 2023.
  • The 3-year median for Non-Current Deferred Tax Liability is $2.4 billion (2024), against an average of $2.5 billion.
  • The largest annual shift saw Non-Current Deferred Tax Liability dropped 16.31% in 2023 before it increased 7.61% in 2024.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $2.7 billion in 2022, then dropped by 16.31% to $2.2 billion in 2023, then rose by 7.61% to $2.4 billion in 2024.
  • Per Business Quant, the three most recent readings for NVS's Non-Current Deferred Tax Liability are $2.4 billion (Q4 2024), $2.2 billion (Q4 2023), and $2.7 billion (Q4 2022).